Shots:

• Merck to acquire all outstanding shares of Pandion for $60/share in cash- representing the equity value of ~$1.85B. The transaction is expected to close in H1’21
• The acquisition will strengthen Merck’s portfolio with the addition of candidates targeting a broad range of autoimmune diseases
• Pandion is advancing a pipeline of precision immune modulators targeting critical immune control nodes along with its lead candidate (PT101) intended to treat UC and other autoimmune diseases

 ­ Ref: Businesswire | Image: Merck